Method of producing derivatives of pyridazine

专利摘要:
La présente invention concerne: - les composés de formule dans laquelle X1 représente N ou X2 représente N ou à la condition que X1 et X2 soient différents l'un de l'autre, R1 et R2 étant -(CH2)nOH ou bien représente un hétérocycle à 5 ou 6 chainons substitue en position 3 ou 4 par exemple par-(CH2)mOR6 où R6 est H ou un reste acyle ou un reste amido, - un procédé de préparation desdits composés; - et les médicaments actifs notamment sur le système nerveux central contenant lesdits composés.
公开号:SU1342415A3
申请号:SU843696574
申请日:1984-01-20
公开日:1987-09-30
发明作者:Бизьер Катлеен；Шамбон Жан-Пьер；Аллот Андре
申请人:Санофи (Фирма)；
IPC主号:

专利说明:

one
This invention relates to a process for the preparation of pyridazine derivatives, new biologically active compounds that can be used in medicine.
The purpose of the invention is to obtain new pyridazine derivatives with higher anticonvulsant activity, as well as hypnotic and calming activity while maintaining low toxicity.
Example 1. 3- (4-hydroxypiperidine) -6- (2-nitrophenyl) -pyridazine (SR 41673).
3 g of 3-chloro-6-2-nitrophenyl) -pyridazine are mixed with 3.86 g of 4-hydroxypyridine in 60 ml of n. butanol and heated with stirring at 100 ° C for 5 hours.
The reaction mixture was concentrated in vacuo to dryness, then the residue was dissolved in water and extracted into ethyl acetate. The organic phase is washed with water, dried over sodium sulfate and concentrated to dryness. The resulting oil is chromatographed on silica gel using chloroform-methanol (90:10) as eluent. After evaporation of the solvents, the remaining oil crystallizes. Recrystallization is carried out in acetonitrile to obtain 2.6 g of the desired compound, m.p. 138-139 ° C, yield 68%.
PRI mme r 2. 3- (4-hydroxypiperidine) -6- (2-chlorophenyl) -pyridazine (CM 40907).
5 g of 3-chloro-6- (2-chlorophenyl) pyridazine is dissolved in 120 ml of n. butanol and mixed with 6.74 g of 4-hydroxy-ridine, then heated at reflux. In accordance with the conditions given in Example 1B, after recrystallization in absolute ethanol, 5 g of the expected product are obtained, m.p. 154- 155 C.
PRI me R 3. 3- (4-Butyroyloxypiperidine) -6- (2-chlorophenyl) -pyridazine (SR 41172).
2.9 g of the compound obtained in Example 2 is dissolved in 100 ml of tetrahydrofuran, then 3.5 ml of triethylamine and 2.6 g of butyryl chloride are added, after which the mixture is heated under reflux for 3 days. 0.7 ml of triethylamine and 0.52 ml of butyryl chloride are added and the mixture is heated again with reflux for 24 hours. The reaction mixture is then concentrated dry and the residue

Q
15
20
25 Q
35
45
50 55 152
the current is dissolved in 1N. hydrochloric acid, followed by washing in ether.
After the addition of sodium carbonate, it is extracted in ethyl acetate. The organic phase is dried over sodium sulfate and concentrated to dryness. The resulting oil is chromatographed on silica gel using ethn-acetate as eluant. After concentration and recrystallization in isopropyl ether, 2.7 g of SR 41172 are obtained, m.p. 89-90 ° C.
EXAMPLE 4 3- (4-Methylcarbamoyl-ilipo-sipiperidine) -6- (2-chlorophenyl) -pyridazine, (SR 41820). ,
2.7 g of the compound obtained in Example 2 is dissolved in 50. ml of tetrahydrofuran. The solution is heated at reflux for 48 hours in the presence of 1.65 ml of methyl isocyanate, after which another 1.65 ml of methyl isocyanate is added, heating is continued for 48 hours.
The reaction mixture is concentrated in vacuo, the residue is chromatographed on silica gel using ethyl acetate as eluent. After concentration, the compound is recrystallized in ethyl acetate. Get 1 g SR 41820, so pl. 134-136 ° C.
Example 5. 4- (4-Dimethylcarbamoyl-sipiperidine) -6- (2,4-dichlorophenyl) -pyridazin (SR 42432).
A.3- (4-hydroxypiperidine) -6- (2,4-dichlorophenyl) -pyridazine (SR 41378).
Actually as in Example 1, using 3-chloro-6- (2,4-dichlorophenyl) -pyridazine and 4-hydroxypiperidine as the starting compound.
In the same way receive the target compound, so pl. 15 -153 ° C (ethanol), yield 77.6%.
B.SR 42432.
4.7 g of the obtained compound are dissolved in 60 ml of dioxane, then 6.3 ml of triethylamine and 4.7 ml of dimethylcarbamoyl chloride are added. Heating is carried out under reflux for 7 days, after which the solvent is evaporated to dryness under vacuum. The residue was dissolved in an aqueous solution (10% -1N ohm) of sodium carbonate and extracted in ethyl acetate. The organic phase is separated, dried on sodium sulfate and the solvent is evaporated to dryness in vacuo. The residue is subjected to silica gel chromatography using ethyl acetate as an eluent.
The resulting substance is crystallized. After recrystallization in this acetate, the desired product is obtained, mp. G96-198 C; yield 2.8 g
EXAMPLE 6, 4-Dioxa-8-aza-spirodec (4,5) -8-yl-6- (2-chloro-phenes-1) pyridazine (SE 42487).
A mixture of 4.5 g of H-chloro-6- (2-chlorophenyl) pyridazine and 8.2 g of 1,4-dioxa-8-aza-spirodecane (4,5) in 100 ml is heated under reflux for 18 hours. ml of butanol. The butanol is evaporated to dryness in vacuo and the residue is dissolved in water. Extracted with ethyl acetate and dried the organic solution on sodium sulfate. The solvent is evaporated to dryness in vacuo and the residue is recrystallized in ethyl acetate. Get the target product, so pl. 156-158 C, yield 5.2 g.
Example. 3- (4-Oxopiperidine) -6- (2-chlorophenyl) -pyridazine (SR 42488).
Heating is carried out at reflux for 4 hours 4 g of the compound obtained in example 6, dissolved in sms, 40 ml of formic acid and 60 ml of water. The reaction mixture is poured into a solution of sodium hydroxide, supersaturated with ice, extracted with methylene chloride, the organic layer is separated and dried on sodium sulfate.
The solvent is evaporated to dryness in vacuo, after which the residue is recrystallized in absolute ethanol. Get the target product, so pl. 158-160 ° C, yield 3.2 g
Using similar methods, the compounds described in Table 2 are obtained.
Biological testing.
Determination of the hypnogenic and sedative effect of compounds.
The effect of compounds on spontaneous mobility.
The sedative effect is manifested in the reduction of the spontaneous mobility of animals. This effect was determined using an actimetric test developed by Boisier and Simon. The test was performed using two Apelat-type actimetric cells (26-21.5 10 cm), illuminated by two light beams, which are fixed by a photocell. The experimental labyles consisted of 12 females with a smaller Charles River CDl weighing 20–24 g each. The animals were placed individually in cages for 45 min after administration.
orally studied compounds at a dose of 250 or 100 mg / kg. Each intersection of the light beam was fixed by an individual counter. The corresponding amount of animal movement was recorded for 10 minutes and compared with the number of movements noted in the control animals, which were only treated with an excipient (0.1 N HCl).
The results are shown in Table. 2
After oral administration in a dose of 100 or 250 mg / kg of the proposed compounds, a potent sedative is observed. the effect of these compounds, which is a significant reduction in the mobility of animals.
On the other hand, a dose of 100 mg / k of compound CM 41378 results in a loss of the characteristic reflex of the inversion of the inductive effect in 60% of treated animals;
B. Ability to increase the anesthesia achieved by pentobarbital.
The dp of refining hypnogenic dyes of the proposed compounds has been studied for their ability to enhance the effect achieved by a single subarcone dose of pentobarbital, using mice as an example. Experimental animals consisted of 10 Charles River CDl weighing 20-24 g each. Pentobar Betal (20 mg / kg, b) was administered 60 minutes after the oral administration of the proposed compound to mice. The criterion of the marked backfill was the loss of the reflex of turns.
The ability to enhance the effect of pentobarbital, mg / kg:
CM 40907 96
SR 4115520
SR 4137821
SR 420957.4
SR 4248867
The proposed compounds are capable of enhancing the narcotic effect of pentobarbital; This property is a predicative hypnogenic effect.
Evaluation of the anticonvulsant effect of the compounds.
The anticonvulsant effects of the proposed compounds on mice were evaluated on a model of convulsions caused by electric shock, and on a model of convulsions caused by the chemical substance biculine.
Antagonism of convulsions caused by electric shock
This test was slightly modified compared to the Swing Rada Azami test. A Casta pulse generator equipped with 2 ocular electrodes was used, giving a current of 12.5 V for 0.3 s. Batch of animals consisted of 10 Charles Rivers GDI mice weighing 20-24 g each. The compounds were orally administered to the animals 60 minutes before the electroshock. Animals that did not exhibit tonic rectification of the hind limbs were regarded as protected from convulsive crisis.
Antagonism of convulsions caused by biculinum.
Batch of animals consisted of 10 Charles Rivers GDI mice weighing 20-24 g each. Compounds were orally administered 60 minutes before the administration of bicculin (0.8 mg / kg, iv). The appearance of tonic convulsions was observed within 60 minutes after the administration of bicculine.
The results are shown in Table. 3
After oral administration of the proposed compounds, the anticonvulsant properties of these compounds with respect to electroshock and the action of bicculine are shown.
Determination of the lethal dose of ds mouse after the rapid administration of compounds
The compounds were administered orally to batches of animals from 5 female Charles Rivers GDI mice weighing 20-24 g as a solution in 0.1 N hydrochloric acid.
Toxicity manifested within 72 hours after administration of the compounds. Lethal dose (I Ljo was calculated for two compounds.
The results (in percent), showing the number of animals that died within 71 hours after the oral administration of the proposed compounds, are given in Table. four.
The experiments thus conducted show that the compounds proposed have low toxicity, have a higher anticonvulsant activity than sodium valproate and, in addition, show soothing and hypnotic activity.

权利要求:
Claims (1)
[1]
Invention Formula
The method of producing pyridazine derivatives of general formula I
Hg
where Ar is a group
, "3 R
R, is hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitro, or cyano; Cd is hydrogen or halogen,
Ar - unsubstituted naphthyl group;
X.
de R, Ra
/ Rr
- group-С-NV
five.
and
make up with the nitrogen atom to which they are bound, one of the following 1x groups of piperidine or pyrroline;
.
about
RI
wherein the piperidine group is substituted at the 3- or 4-position by a group R, meaning -OH; ,-HE; .
about
AT
-0-and-0-c-n
RB
R
9
II Oh
where rg and
R - independently of each other
hydrogen or lower alkyl,
and in the 4th position with an oxo group or a 1,3-spiro-dioxolane 2-yl group, or the pyrroline group is substituted at the 4-position with the -OH or -CH20H group; characterized in that the compound of formula II is reacted
C1
where Ar has the indicated meanings with an amine of the formula
/ KGch
R.
de R and R form with the nitrogen atom to which they are bonded, either a piperidine group substituted at the 3- or 4-position with the (CH2) -OH group, where is either 2 or the 4-position with the 1.37 group. 134
spirodioxolan-2-yl, or a pyrroline group substituted at the 4-position with a hydroxy group or CH jOH; in alcohol at the boiling point of the mixture and, if necessary, convert the resulting compound of general formula I, / KI
where X, is a group-C-NC where B,
 t
R
R
 form with the nitrogen atom to which oyi are bound, the piperidine group substituted at the 3- or 4-position with the OH group;
ester by the action of an acid chloride in the presence of a tertiary amine in an aprotic solvent, in an N-monosubstituted carbamate by the action of an alkyl isocyanate, heating
58
the mixture in an aprotic solvent, BH, M-disubstituted carbamate by the action of carbamyl chloride in a solvent at the boiling point of the mixture and in the presence of a hydrogen acid acceptor, transform the resulting compound of general formula 1, where Xj is the group
/ Kg h -C - N)
Rf
where R, and Rj with the nitrogen atom to which they are bonded, the piperidine group substituted at the 4-position by the spirodioxolane group, by hydrolysis in an acidic medium to the corresponding oxo derivative.
Table 1
12
V
.
AH
41096 cm
HE
41127 SR 41155 SR 41171
154 (ethyl acetate) 56.9
174-176 (absolute. E anol) 62.9
150-152 (ethyl acetate) 80.2
150 (acetonitrile) 47.9
134241510
Continuation of table 1
tonitrile) 70.7
42087
42095
42095
Cl
-N (O-CO-TJIH. Us1 SSNz) s SNz
-yr (o-son jQ b d
CH-i .t / CHz CH
-NQ O-CO-N - X.. C1
SR 42159
-K (UON
SR 42356
nol) 70
156-158 (ethyl acetate) 69.6

154-155 (ethyl acetate - pr. Isopropyl ether) 40.8
131 (ethyladetate-ave. Isopropyl ether) 34.4
136-138 (ethyl acetate-pr. Isopropyl ether) 64.3
187-188 (methanol) 26.6
SR 42368
SR 42399
176-178 (ethyl acetate) 16.5
148-150 (ethyl acetate) 21.3
Compound
BHD,,%, with oral dose, mg / kg 250 G 500 I 1000
CM 40907 CM 41127 SR 41155 SR 41171 SR 41172 SR 41184 SR 41185 SR 41188 SR 41254
Table 4
7
100 100 100 100
about
60 10
Editor I.Rybchenko
Compiled by V. Volkov Tehred I. Popsvich
Order 4447/58 Circulation 371Subscription
VNISh State Committee of the USSR
for inventions and discoveries 113035, Moscow, Zh-35, Raushsk nab., 4/5
Production and printing company, Uzhgorod, st. Project, 4
Proofreader N.Korol

类似技术:

---

公开号 | 公开日 | 专利标题

---

Casida et al.1976|Structure-toxicity relationships of 2, 6, 7-trioxabicyclo [2.2. 2]-octanes and related compounds

---

SU1342415A3|1987-09-30|Method of producing derivatives of pyridazine

---

SU682134A3|1979-08-25|Method of preparation of erytromycin derivatives or salts thereof

---

EP0088593B1|1987-05-27|1,2,4-triazine and pyrazine derivatives

---

CS229941B2|1984-07-16|Production method of aminated pyridazine derivatives

---

SK283536B6|2003-09-11|Pyridyl-phtalazin diones, process for their production and use and pharmaceutical compositions based on them

---

SU1356960A3|1987-11-30|Method of producing derivatives of pyridazine

---

EP0254627A1|1988-01-27|Derivatives of benzhydryloxyethylpiperazine, processes for their preparation and pharmaceutical compositions containing them

---

US4691018A|1987-09-01|Pyridine derivatives and their use as anti-allergic agents

---

DD233847A5|1986-03-12|PROCESS FOR THE PREPARATION OF METHYLENEDIPHOSPHONE DERIVATIVES WITH ANTIREUMATIC PROPERTIES

---

KR890001425B1|1989-05-03|Pyrido 2,3-d pyrimidine-5-ones and process for preparation thereof

---

FR2483929A1|1981-12-11|NOVEL N6-SUBSTITUTED ADENOSINS USEFUL AS ANTIHYPERTENSIVE DRUGS, THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM, AND PROCESS FOR THE PREPARATION THEREOF

---

JPH05194395A|1993-08-03|N-alkylated 1,4-dihydropyridinedicarboxylic acid ester

---

CS199744B2|1980-07-31|Process for preparing derivatives of 2-hydrazonpropionic acid

---

US4104385A|1978-08-01|Cyclic alkylidenyl N-[6-|-3-pyridazinyl]aminomethylenemalonates

---

US3920687A|1975-11-18|2,3,6,7-tetrahydro-6-phenyl-5h-imidazo|+8 1,4)benzodiazepin-5-ones and diazepines

---

US3758546A|1973-09-11|Methoxy amine derivatives and process for preparing them

---

US4654369A|1987-03-31|Esters of 2-|-6-nitro-benzoic acid and pharmaceutical compositions

---

SU795469A3|1981-01-07|Method of preparing uracyl derivatives

---

US2934535A|1960-04-26|Z-amino-x-trifluoromethylanilino-s

---

US3846412A|1974-11-05|Dihydro-2-amino-isoquinolines and their derivatives

---

EP0197386A1|1986-10-15|2-| derivatives of 6-nitrobenzoic acid, process for their preparation and pharmaceutical compositions containing them

---

RU2128651C1|1999-04-10|N-butylamide 2-anilino-6,7-dihydro-5h-pyrindine-3- carboxylic acid having anti-inflammatory activity

---

EP0032856A1|1981-07-29|2,3-Dihydroimidazo | pyridazine derivatives, process for their preparation and their therapeutical use

---

RU2068415C1|1996-10-27|5,7-dihydroxy-2-methyl-8-[4-|-|piperidinyl]-4h-1-benzopyran-4-one or its stereoisomers or pharmacologically acceptable acid-additive salts and a method of their synthesis

同族专利:

---

公开号 | 公开日

---

IL70740A|1986-09-30|

---

FI79537C|1990-01-10|

---

ZA84342B|1984-08-29|

---

AT28453T|1987-08-15|

---

SG2189G|1989-06-02|

---

EP0114770A3|1984-08-22|

---

CA1217490A|1987-02-03|

---

FI840238A0|1984-01-20|

---

KR910000640B1|1991-01-31|

---

IE840102L|1984-07-21|

---

PT77966B|1986-07-11|

---

PL245836A1|1985-07-02|

---

PT77966A|1984-02-01|

---

FI840238A|1984-07-22|

---

DK25684D0|1984-01-20|

---

NO159170C|1988-12-07|

---

PH21060A|1987-07-10|

---

DD216014A5|1984-11-28|

---

US4624952A|1986-11-25|

---

FI79537B|1989-09-29|

---

NZ206906A|1987-05-29|

---

ES8407040A1|1984-09-01|

---

NO840214L|1984-07-23|

---

OA07638A|1985-05-23|

---

PL143224B1|1988-01-30|

---

CS42484A2|1985-08-15|

---

GR79766B|1984-10-31|

---

HU191586B|1987-03-30|

---

CS242894B2|1986-05-15|

---

AU563160B2|1987-07-02|

---

YU10384A|1986-10-31|

---

MA20007A1|1984-10-01|

---

IL70740D0|1984-04-30|

---

NO159170B|1988-08-29|

---

AU2323684A|1984-07-26|

---

FR2539741A1|1984-07-27|

---

EG16212A|1989-06-30|

---

JPS59137469A|1984-08-07|

---

FR2539741B1|1985-05-17|

---

DE3464909D1|1987-08-27|

---

KR840007406A|1984-12-07|

---

DK25684A|1984-07-22|

---

EP0114770B1|1987-07-22|

---

ES528921A0|1984-09-01|

---

EP0114770A2|1984-08-01|

---

IE56569B1|1991-09-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

GB1345880A|1971-06-18|1974-02-06|Cepbepe|Pyridazine derivatives|

---

US4302455A|1980-04-14|1981-11-24|Merck & Co., Inc.|2-pyrazines|

---

FR2510997B1|1981-08-10|1984-02-10|Sanofi Sa|

---

FR2511366B1|1981-08-11|1984-12-14|Sanofi Sa|US5001125A|1984-03-26|1991-03-19|Janssen Pharmaceutica N.V.|Anti-virally active pyridazinamines|

---

FR2567518B1|1984-07-11|1987-11-13|Sanofi Sa|NOVEL NITROGEN HETEROCYCLIC CORE COMPOUNDS, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THE SAME|

---

DE3517617A1|1985-05-15|1986-11-20|Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München|NEW PYRIDAZINIUM COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR FUNGICIDES AND ALGICIDES CONTAINING THEM|

---

US5106973A|1987-11-23|1992-04-21|Janssen Pharmaceutica N.V.|Pyridzainamine derivatives|

---

FI895821A0|1988-12-07|1989-12-05|Wellcome Found|PHARMACEUTICAL ACTIVE CNS FOERENINGAR.|

---

US5631255A|1989-02-07|1997-05-20|Sanofi|Pyridazine derivatives|

---

FR2676444B1|1991-05-16|1995-03-10|Sanofi Elf|NOVEL AMINO-3 PYRIDAZINE DERIVATIVES ACTIVE IN THE CENTRAL NERVOUS SYSTEM, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.|

---

US5958934A|1996-05-23|1999-09-28|SyntexInc.|Aryl pyrimidine derivatives and uses thereof|

---

TW440563B|1996-05-23|2001-06-16|Hoffmann La Roche|Aryl pyrimidine derivatives and a pharmaceutical composition thereof|

---

US5952331A|1996-05-23|1999-09-14|SyntexInc.|Aryl pyrimidine derivatives|

---

WO2008096746A1|2007-02-06|2008-08-14|Takeda Pharmaceutical Company Limited|Spiro compound and use thereof|

---

CA2984586C|2015-04-29|2021-02-16|Guangdong Zhongsheng Pharmaceutical Co., Ltd.|Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

FR8300954A|FR2539741B1|1983-01-21|1983-01-21|

---